Trial Profile

A clinical study of CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Aug 2024 According to CASI Pharmaceuticals media release, company anticipate to submit an IND for CID-103 in AMR in the fourth quarter of this year.
28 Jun 2024 New trial record
26 Jun 2024 According to CASI Pharmaceuticals media release, Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com